NICE publishes updated clinical management and service guidance on antenatal and postnatal mental health (CG192)

The guideline has been updated to reflect the MHRA guidance on valproate use by women and girls.

SPS commentary:

The MHRA guidance advises valproate must not be used in any woman or girl able to have children unless there is a pregnancy prevention programme (PPP) in place. This is designed to make sure patients are fully aware of the risks and the need to avoid becoming pregnant.


National Institute for Health and Care Excellence

Resource links:

MHRA advice